Unbound MEDLINE

Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] Journal article

 
TitleRefractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.
Author(s)Lee CH, Su LH, Lin WC, Tang YF, Liu JW 
InstitutionDivision of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 123, Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien 833, Taiwan; Infectious Control Team, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
SourceInt J Infect Dis 2009 Sep 30.
AbstractWe report the case of a patient with vertebral osteomyelitis and concurrent urinary tract infection (UTI) in which extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (EC(1)) isolated from urine culture was ciprofloxacin-resistant and ertapenem/imipenem-susceptible. The empirically used oral form of ciprofloxacin was switched to parenteral ertapenem based on the antimicrobial susceptibility. However, vertebral osteomyelitis deteriorated, and despite the disappearance of pyuria and a negative urine culture, ESBL-producing E. coli was isolated from a biopsy of the bony material from the fifth lumbar vertebra (EC(2)) and blood culture (EC(3)) at 10 and 12 days after starting ertapenem, respectively. Ertapenem was switched to imipenem, and defervescence occurred 2 days later; a subsequent blood culture was negative. Genotyping indicated that EC(1), EC(2), and EC(3) were of the same clone, with the ESBL being CTX-M-14. The tested antibiotics had identical minimum inhibitory concentrations against each of these isolates. From the pharmacokinetics/pharmacodynamics points of view, it is reasonable to attribute the ertapenem treatment failure in vertebral osteomyelitis due to ESBL-producing E. coli in this case to the suboptimal ertapenem concentration in the inflammatory bone tissue of the host.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19800278
  
Advertise on this site.